目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS AND REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 RESEARCH DESIGN
2.1.2 SECONDARY DATA
2.1.3 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARIES
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024)
4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024
4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030
4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing burden of chronic diseases
5.2.1.2 Advancements in drug delivery technologies
5.2.1.3 Higher patient compliance and preference for oral route
5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
5.2.2 RESTRAINTS
5.2.2.1 High cost of drug development
5.2.2.2 Contraindication of oral proteins & peptides
5.2.2.3 Stringent regulatory approval process
5.2.3 OPPORTUNITIES
5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
5.2.3.2 Growing demand for personalized medicine
5.2.4 CHALLENGES
5.2.4.1 Hurdles in formulation and stability
5.2.4.2 Availability of alternative therapies
5.3 ECOSYSTEM ANALYSIS
5.3.1 ROLE OF RAW MATERIAL VENDORS
5.3.2 ROLE OF PRODUCT PROVIDERS
5.3.3 ROLE OF END USERS
5.3.4 ROLE OF REGULATORY AUTHORITIES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 KEY STAKEHOLDERS & BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS
5.7.2 BUYING CRITERIA
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE, BY KEY PLAYER
5.8.2 AVERAGE SELLING PRICE, BY COUNTRY & REGION
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY SCENARIO
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Transient permeation enhancers
5.11.1.2 Gastrointestinal permeation enhancement technology
5.11.1.3 Oral sCT (OSTORA) technology
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Peptelligence
5.11.2.2 ThioMatrix
5.11.2.3 Transferrin-based recombinant fusion proteins
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Oramed and Orasome
5.11.3.2 Q-sphera
5.11.3.3 Nanoinclusion
5.11.3.4 Oleotec and Soctec
5.12 PIPELINE ANALYSIS
5.13 PATENT ANALYSIS
5.13.1 METHODOLOGY
5.13.2 PATENTS APPLIED AND GRANTED, 2014-2025
5.14 REIMBURSEMENT SCENARIO
5.15 KEY CONFERENCES & EVENTS, 2025-2026
5.16 INVESTMENT & FUNDING SCENARIO
5.17 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
5.18 IMPACT OF 2025 US TARIFFS-ORAL PROTEINS & PEPTIDES MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRIES/REGIONS
5.18.4.1 US
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON MANUFACTURING INDUSTRIES
5.18.6 RECOMMENDATIONS FOR MANUFACTURERS

6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
6.1 INTRODUCTION
6.2 SEMAGLUTIDE
6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
6.3 CALCITONIN
6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
6.4 LINACLOTIDE
6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
6.5 TROFINETIDE
6.5.1 FDA APPROVAL TO DRIVE MARKET
6.6 VOCLOSPORIN
6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
6.7 PLECANATIDE
6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
6.8 OTHER MOLECULES

7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
7.1 INTRODUCTION
7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
7.4 GUANYLATE CYCLASE-C AGONISTS
7.4.1 RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET
7.5 GLYCINE-PROLINE-GLUTAMATE
7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
7.7 OTHER DRUG CLASSES

8 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
8.1 INTRODUCTION
8.2 TABLETS
8.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
8.3 CAPSULES
8.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
8.4 ORAL SOLUTIONS
8.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH

9 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 DIABETES
9.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
9.3 CNS DISORDERS
9.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
9.4 GASTROENTEROLOGY
9.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
9.5 GENETIC DISORDERS
9.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
9.6 NEPHROLOGY
9.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
9.7 OBESITY & OVERWEIGHT
9.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
9.8 OTHER THERAPEUTIC AREAS

10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOME CARE SETTINGS
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
10.4 HOSPITALS & SPECIALTY CLINICS
10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET

11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 US to hold large shares in North American and global markets
11.2.3 CANADA
11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Germany to hold largest share of European market
11.3.3 UK
11.3.3.1 Strong focus on advancement of life sciences to support market growth
11.3.4 FRANCE
11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
11.3.5 ITALY
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
11.3.6 SPAIN
11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
11.3.7 NETHERLANDS
11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Increasing R&D expenditure to drive market
11.4.3 JAPAN
11.4.3.1 Increasing prevalence of diabetes to drive market
11.4.4 INDIA
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
11.4.5 AUSTRALIA
11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Brazil to hold largest market share in Latin America
11.5.3 MEXICO
11.5.3.1 Growing diabetes and obesity cases to drive market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
11.6.2.2 UAE
11.6.2.2.1 Regulatory approvals for GLP-1 drugs to propel market
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
12.3 REVENUE ANALYSIS, 2022-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX
12.5.1 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1.1 Stars
12.5.1.2 Emerging leaders
12.5.1.3 Pervasive players
12.5.1.4 Participants
12.5.2 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024
12.5.2.1 Stars
12.5.2.2 Emerging leaders
12.5.2.3 Pervasive players
12.5.2.4 Participants
12.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.3.1 Company footprint
12.5.3.2 Region footprint
12.5.3.3 Molecule footprint
12.5.3.4 Formulation footprint
12.5.3.5 Therapeutic area footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of key startups/SMEs
12.7 VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 NOVO NORDISK A/S
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product launches & approvals
13.2.1.3.2 Deals
13.2.1.3.3 Expansions
13.2.1.3.4 Other developments
13.2.1.4 MnM view
13.2.1.4.1 Right to win
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses & competitive threats
13.2.2 ABBVIE INC.
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product approvals
13.2.2.3.2 Deals
13.2.2.4 MnM view
13.2.2.4.1 Right to win
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses & competitive threats
13.2.3 PFIZER INC.
13.2.3.1 Business overview
13.2.3.2 Product pipeline
13.2.3.3 Recent developments
13.2.3.3.1 Product approvals
13.2.3.3.2 Deals
13.2.3.3.3 Other developments
13.2.3.4 MnM view
13.2.3.4.1 Right to win
13.2.3.4.2 Strategic choices
13.2.3.4.3 Weaknesses & competitive threats
13.2.4 BAUSCH HEALTH COMPANIES INC.
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product approvals
13.2.5 CHIESI FARMACEUTICI S.P.A.
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.5.3 Recent developments
13.2.5.3.1 Deals
13.2.6 ACADIA PHARMACEUTICALS INC.
13.2.6.1 Business overview
13.2.6.2 Products offered
13.2.6.3 Recent developments
13.2.6.3.1 Product approvals
13.2.7 AURINIA PHARMACEUTICALS INC.
13.2.7.1 Business overview
13.2.7.2 Products offered
13.2.7.3 Recent developments
13.2.7.3.1 Product approvals
13.2.8 MERCK & CO., INC.
13.2.8.1 Business overview
13.2.8.2 Product pipeline
13.2.8.3 Recent developments
13.2.8.3.1 Deals
13.2.8.3.2 Other developments
13.2.9 JOHNSON & JOHNSON SERVICES, INC.
13.2.9.1 Business overview
13.2.9.2 Product pipeline
13.2.9.3 Recent developments
13.2.9.3.1 Other developments
13.2.10 SWK HOLDINGS
13.2.10.1 Business overview
13.2.10.2 Product pipeline
13.2.10.3 Recent developments
13.2.10.3.1 Other developments
13.2.11 R-PHARM JSC
13.2.11.1 Business overview
13.2.11.2 Products in pipeline
13.2.12 ENTERA BIO LTD.
13.2.12.1 Business overview
13.2.12.2 Product pipeline
13.2.12.3 Recent developments
13.2.12.3.1 Deals
13.2.12.3.2 Other developments
13.2.13 PROXIMA CONCEPTS
13.2.13.1 Business overview
13.2.13.2 Products in pipeline
13.3 OTHER PLAYERS
13.3.1 ASTRAZENECA PLC
13.3.2 REGOR THERAPEUTICS GROUP
13.3.3 TERNS PHARMACEUTICALS, INC.
13.3.4 STRUCTURE THERAPEUTICS
13.3.5 VIKING THERAPEUTICS
13.3.6 PROTAGONIST THERAPEUTICS INC.
13.3.7 RANI THERAPEUTICS
13.3.8 CARMOT THERAPEUTICS, INC.
13.3.9 ZEALAND PHARMA
13.3.10 SCIWIND BIOSCIENCES CO., LTD.
13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS